Johnson B, et al. - This study aimed at determining the impact of metastasectomy for patients with BRAF V600E metastatic colorectal cancer (mCRC). As per findings, researchers suggested considering multimodality therapy incorporating metastasectomy for BRAF V600E mCRC, in select patients, this could enhance overall survival.

Methods

• Researchers analyzed patients with BRAF V600E mCRC for clinical characteristics and survival using prospective clinical and molecular data.
• In this study, for statistical analyses, they utilized the Kaplan-Meier method, log-rank test, and Cox proportional hazard models.

Results

• Researchers identified 52 patients between July 1, 2008, and January 4, 2016; median age was 65 years, 61% were female, Eastern Cooperative Oncology Group performance status was ≤1, 71% had right-sided tumors, and 28% had liver-limited metastasis.
• In the first-line setting, 7% (4/52) were administered fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (BEV) and 81% received doublet chemotherapy consisting of fluoropyrimidine, oxaliplatin, and BEV.
• For all 52 patients, median overall survival (OS) was 25 months with median progression-free survival (PFS) of 9.3 months.
• With median follow-up of 18.3 months, metastasectomy in 21 patients led to a longer OS (29.1 months vs. 22.7 months, hazard ratio [HR] = 0.33; confidence interval [CI], 0.12–0.78; p = .01) and PFS (13.6 months vs. 6.2 months, HR = 0.53, CI, 0.28–0.97; p = .03) compared with the non-metastasectomy cohort.
• Multivariate analysis suggested metastasectomy as crucial for improved survival outcomes (HR = 0.52; 95% CI, 0.07–1.02; p = .02).
• After metastasectomy, median disease-free survival was 9.7 months (95% CI, 5.5–19.5).
• At the time of last follow-up, two patients remain disease-free, with one patient without relapse for greater than 2 years (28.9 months).